Article

ERK Hyperactivation Represents a Unified Mechanism of Escape in Intrinsic and Acquired CDK4/6 Inhibitor Resistance in Acral Lentiginous Melanoma

2022-09-16

Abstract excerpt

<title>Abstract</title> <p>Patients with metastatic acral lentiginous melanoma (ALM) suffer worse outcomes relative to patients with other forms of cutaneous melanoma (CM), and do not benefit as well to approved melanoma therapies. Identification of cyclin-dependent kinase 4 and 6 (CDK4/6) pathway gene alterations in >60% of ALMs has led to clinical trials of the CDK4/6 inhibitor (CDK4i/6i) palbociclib for ALM; h...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d22bc6ab-0de7-5e9b-bcb7-7d7db30e8d89
DOI: 10.21203/rs.3.rs-2023316/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

ERK Hyperactivation Represents a Unified Mechanism of Escape in Intrinsic and Acquired CDK4/6 Inhibitor Resistance in Acral Lentiginous MelanomaDOI 10.21203/rs.3.rs-2023316/v1Read

ERK Hyperactivation Serves as a Unified Mechanism of Escape in Intrinsic and Acquired CDK4/6 Inhibitor Resistance in Acral Lentiginous MelanomaSemantic proximity Read

ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanomaSemantic proximity Read

Genetic characteristics and response to systemic therapies of acral lentiginous melanoma at a tertiary care center-a retrospective review.Semantic proximity Read

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in CancerSemantic proximity Read

Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.Semantic proximity Read

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistanceSemantic proximity Read

Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An UpdateSemantic proximity Read

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in MelanomaSemantic proximity Read

Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironmentSemantic proximity Read

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.Semantic proximity Read

Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.Semantic proximity Read

The MEK/ERK Network as a Therapeutic Target in Human CancerSemantic proximity Read